SAMS.EL.0,5SP.GDRS144A/95/ US7960508882 /
2024-07-26 8:30:16 PM | Chg. +5.00 | Volume | Bid8:30:22 PM | Ask8:30:22 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
1,350.00EUR | +0.37% | 0 Turnover: 0.00 |
-Bid Size: - | -Ask Size: - | 318.42 bill.EUR | - | - |
GlobeNewswire
07-01
FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar to Stelara
GlobeNewswire
06-26
Primarius NanoSpice™ Simulator Certified for Samsung Foundry 3nm/4nm Process Technology
GlobeNewswire
06-25
Pixalate Releases Top 100 Connected TV (CTV) Bundle ID Rankings For Global Open Programmatic Ad Spen...
GlobeNewswire
06-25
Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D ...
GlobeNewswire
06-14
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimila...
GlobeNewswire
05-15
Pixalate’s April 2024 Top Grossing Connected TV (CTV) Apps Based on Global Open Programmatic Ad Reve...
GlobeNewswire
05-09
Pixalate Releases Top 100 Connected TV (CTV) Bundle ID Rankings For Global Open Programmatic Adverti...
GlobeNewswire
05-02
Pixalate Releases LATAM Q1 2024 Connected TV (CTV) Device Market Share Report: Roku Leads with 39% M...